, Volume 22, Issue 4, pp 395-400,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 02 Sep 2010

Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome


Introduction and hypothesis

In order to better understand provider treatment patterns for interstitial cystitis (IC)/painful bladder syndrome, we sought to document the therapies utilized and their associated expenditures using a national dataset.


A cohort was created by applying the ICD-9 diagnosis of IC (595.1) to INGENIX claims for the year 1999. Subjects were followed for 5 years, and patterns of care and related expenditures were evaluated.


Of 553,910 adults insured in 1999, 89 subjects had a diagnosis of IC with 5-year follow-up data. All subjects were treated with oral medication(s), 26% received intravesical treatments, and 22% underwent hydrodistension. Total expenditures per subject were $2,808.


The majority of IC expenditures were attributable to oral medical therapy. Hydrodistension and intravesical instillations were utilized in less than 25% of patients. Hydrodistension was used more frequently among subjects with a new diagnosis; this may reflect its utilization as part of a diagnostic algorithm.

Presented at the Society for Urodynamics and Female Urology Annual Meeting, Las Vegas, February 2009